Pfizer Internal News Today

The $11.6 billion agreement will see Pfizer acquire Biohaven’s calcitonin gene-related peptide programmes, including migraine treatment rimegepant.

Acquiring Biohaven is Pfizer’s biggest deal in years and will allow the company to commercialise the Nurtec medication for migraine attacks.

Pfizer Inc. (NYSE: PFE) and Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced that the companies have entered into a definitive agreement under which Pfizer will acquire Biohaven, the maker of NURTEC® ODT, an innovative dual-acting migraine therapy approved for both acute treatment and ...

Pfizer made the splash of the young week Tuesday morning, inking an acquisition deal with New Haven, Connecticut-based Biohaven Pharma totaling $11.6 billion.

Pfizer Inc. (NYSE: PFE) and Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced that the European Commission (EC) has granted marketing authorization for VYDURA (rimegepant), a

/PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) and Pfizer Inc. (NYSE: PFE) today announced that the Committee for Medicinal Products...

NEW HAVEN, Conn., and NEW YORK, January 5, 2022 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) and Pfizer Inc. (NYSE: PFE), today announced that the parties have completed the collaboration transaction between the two companies. The transaction agreements, including Pfizer’s commercialization of rimegepant and zavegepant outside of the U.S., have become effective following the receipt of required regulatory approvals and the satisfaction of other customary condition...

Hits: 1077 Myovant and Pfizer to jointly develop and commercialize ORGOVYX™ (relugolix) and relugolix combination tablet and share profits and expenses in the U.S. and Canada Myovant to receive an upfront payment of $650 million in addition to potential regulatory and sales milestones for a total payment of up to $4.2 billion BASEL, Switzerland and NEW YORK, NY, USA I December 28, 2020 I Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced a collaboration to develop ...

Date Time Myovant Sciences and Pfizer Announce Collaboration to Develop and Commercialize relugolix (GLOBE NEWSWIRE) — Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced a collaboration to develop and commercialize relugolix – a once-daily, oral gonadotropin-releasing hormone (GnRH) receptor antagonist – in oncology and women’s health in the U.S. and Canada. Pfizer will also receive an exclusive option to commercialize relugolix in oncology outside the U.S. and Ca...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Myovant Sciences and Pfizer Announce Collaboration to Develop and Commercialize Relugolix in ... Myovant Sciences, Inc.December 28, 2020 GMT Myovant and Pfizer to jointly develop and commercialize ORGOVYX™  (relugolix) and relugolix combination tablet and share profits and expenses in the U.S. and Canada Myovant to receive an upfront payment of $650 million in addition to potential regulatory and s...